morphine sulfate; naltrexone hydrochloride - Profile

« Back to Dashboard

What are the generic drug sources for morphine sulfate; naltrexone hydrochloride and what is the scope of freedom to operate?

Morphine sulfate; naltrexone hydrochloride is the generic ingredient in one branded drug marketed by Alpharma Pharms and is included in one NDA. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Summary for morphine sulfate; naltrexone hydrochloride

International Patents:	74
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for morphine sulfate; naltrexone hydrochloride

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	20 mg/0.8 mg	022321	1	2018-08-16
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	022321	1	2010-05-28
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	60 mg/2.4 mg	022321	1	2010-05-25
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	100 mg/4 mg	022321	1	2010-05-03

US Patents and Regulatory Information for morphine sulfate; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No			Y

Expired US Patents for morphine sulfate; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009

International Patents for morphine sulfate; naltrexone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Austria	E552829
Australia	2007261451	Pharmaceutical compositions
Australia	2013257508
Australia	2016238844	PHARMACEUTICAL COMPOSITIONS
Australia	2018201915	PHARMACEUTICAL COMPOSITIONS

Investment Scenario, Market Dynamics, and Financial Trajectory for Morphine Sulfate and Naltrexone Hydrochloride

Last updated: February 3, 2026

Executive Summary

This analysis examines the investment landscape, market trends, and financial outlooks for two pharmaceutical compounds: Morphine Sulfate and Naltrexone Hydrochloride. It covers current market sizes, growth drivers, patent statuses, competitive dynamics, regulatory environments, and forecasts applicable to investors considering these drugs.

---

Overview of Morphine Sulfate and Naltrexone Hydrochloride

Parameter	Morphine Sulfate	Naltrexone Hydrochloride
Drug Class	Opioid analgesic	Opioid antagonist
Primary Use	Severe pain management	Opioid and alcohol dependence treatment
Formulation	Oral, injectable, suppository	Oral, injectable
Market Approvals	FDA, EMA	FDA, EMA
Patent Status	Off-patent, generic availability	Patent expired or near-expiry

---

Market Size and Growth Dynamics

Current Market Valuation

Drug	Estimated Global Market Size (2022)	Key Drivers	CAGR (2023-2028)
Morphine Sulfate	~$1.5 billion	Pain management, palliative care	4.2%
Naltrexone Hydrochloride	~$600 million	Substance dependence treatment	3.8%

Sources: [1], [2], [3]

Market Drivers

• Morphine Sulfate

  • Increasing prevalence of chronic and terminal illnesses.
  • Growth in end-of-life care, especially in aging populations.
  • Expanding use in preoperative pain management.

• Naltrexone Hydrochloride

  • Rising opioid and alcohol dependence rates.
  • Increased adoption in outpatient and community treatment programs.
  • Diversification into extended-release formulations.

Market Challenges

• Regulatory scrutiny on opioid misuse and abuse.
• Stringent prescribing guidelines limit market access.
• Competition from alternative analgesics and antagonists.

---

Market Dynamics and Competitive Landscape

Patent and Regulatory Environment

Drug	Patent Status	Regulatory Milestones	Impact on Market
Morphine Sulfate	Off-patent	Established over 50 years	High generic competition, low barriers
Naltrexone Hydrochloride	Patent expired / expiring	Approved in 1984	Incentivizes generic market entry, depresses prices

Major Market Players

Company	Product	Market Share (%)	Focus
Purdue Pharma	MS Contin (morphine)	~25%	Pain management
Janssen	Revia (oral naltrexone)	~15%	Dependence treatment
Endo Pharmaceuticals	Extended-release naltrexone	10-12%	Ongoing growth

Distribution and Sales Channels

• Hospital and hospice settings.
• Community clinics.
• Long-term care facilities.
• Generic distributors for off-patent formulations.

---

Financial Trajectory and Investment Outlook

Revenue Trends

Year	Morphine Sulfate	Naltrexone Hydrochloride
2018	~$1.4 billion	~$550 million
2019	~$1.45 billion	~$580 million
2020	~$1.5 billion	~$600 million
2021	~$1.52 billion	~$615 million
2022	~$1.55 billion	~$620 million

Note: Continued slow growth reflects market maturity and saturation.

Profitability and Pricing

• Marginal profit margins are declining for morphine due to generic competition (~10-15% gross margin).
• For naltrexone, profit margins vary based on formulation (oral vs. injectable); extended-release formulations command higher prices.

Favorable Investment Opportunities

• Increasing focus on Next-Generation formulations with abuse-deterrent features for morphine.
• Expansion into biosimilar or generic markets for both drugs.
• Development of combination therapies.

---

Future Market Opportunities and Risks

Opportunities

• Innovations: Extended-release, abuse-deterrent formulations, or combination drugs.
• New Indications: Exploring off-label uses, e.g., pain adjuncts or psychiatric indications.
• Regulatory Incentives: Orphan drug status or fast-track approval pathways for niche markets.

Risks

• Regulatory: Restrictions due to opioid abuse concerns.
• Pricing Pressure: Increasing use of generics suppresses prices.
• Legal & Ethical Issues: Litigation related to opioid epidemic liability impacts morphine market.
• Market Saturation: Mature markets with limited growth potential.

---

Comparison of Investment Metrics

Metric	Morphine Sulfate	Naltrexone Hydrochloride
Patents	None	Patent expired / expiring
Market Maturity	Mature	Mature
Growth Potential	Moderate	Slightly Moderate
Innovation Pipeline	Limited	Moderate (extended-release)
Regulatory Risk	High (opioid restrictions)	Moderate

---

Comparison with Alternative Therapies

Therapy	Advantages	Disadvantages
Morphine Sulfate	Potent, well-established	Abuse potential, regulatory scrutiny
Naltrexone	Non-addictive, supports abstinence	Limited efficacy in some subpopulations, compliance challenges
Buprenorphine	Partial agonist, lower abuse	More complex prescribing
Gabapentinoids	Broad-spectrum, non-opioid	Off-label risks, dependency concerns

---

FAQs

1. What are the main drivers influencing the market for morphine sulfate?
Demand primarily stems from increasing needs for severe pain management, especially in palliative care, and expanding use in perioperative settings. Demographic shifts toward aging populations also support steady growth.

2. How does patent expiry influence investment prospects in naltrexone hydrochloride?
Patent expiration typically leads to market saturation with generics, reducing revenues for brand-name manufacturers but opening opportunities for lower-cost suppliers. Investment in formulation innovations or niche indications is critical to sustain profitability.

3. What regulatory challenges could impact the growth of these drugs?
Stringent opioid prescribing guidelines, abuse-deterrent requirements, and legislation aiming to curb misuse threaten market expansion, especially for morphine sulfate.

4. Are there emerging trends that could disrupt the market?
Yes. The development of alternative non-opioid analgesics, abuse-deterrent formulations, and expanded use of digital health tools for monitoring adherence could shift market share.

5. Which regions present the most promising investment opportunities?
North America remains the largest market due to high usage and ongoing opioid crisis mitigation efforts. Emerging markets in Asia-Pacific and Latin America offer growth potential due to increasing healthcare infrastructure.

---

Key Takeaways

• Market Maturity: Both morphine sulfate and naltrexone hydrochloride operate in mature markets with steady, moderate growth, primarily driven by demographic factors and expanding indications.
• Patent and Pricing Dynamics: Patent expirations have increased generic competition, compressing margins but lowering barriers for entry and diversification.
• Innovation as a Catalyst: Extended-release formulations, abuse-deterrent features, and combination therapies are crucial for future growth.
• Regulatory Risks: Opioid regulation and abuse concerns remain significant hurdles influencing market trajectory.
• Investment Strategy: Focus on innovation, niche indications, and emerging markets to capitalize on growth opportunities while managing regulatory and legal risks.

---

References

[1] MarketWatch, "Opioid Market Size & Growth," 2022.
[2] GlobalData, "Pharmaceuticals Market Analysis," 2022.
[3] IQVIA, "Top Selling Drugs," 2022.
[4] FDA, "Naltrexone Hydrochloride Approval Details," 1984.
[5] European Medicines Agency, "Morphine Sulfate Summary of Product Characteristics," 2022.